MX2022000606A - Formas polimorficas de (r)-4-(1-((3-(difluorometil)-1-metil-1h-pir azol-4-il)sulfonil)-1-fluoroetil)-n-(isoxazol-3-il)piperidin-1-ca rboxamida. - Google Patents
Formas polimorficas de (r)-4-(1-((3-(difluorometil)-1-metil-1h-pir azol-4-il)sulfonil)-1-fluoroetil)-n-(isoxazol-3-il)piperidin-1-ca rboxamida.Info
- Publication number
- MX2022000606A MX2022000606A MX2022000606A MX2022000606A MX2022000606A MX 2022000606 A MX2022000606 A MX 2022000606A MX 2022000606 A MX2022000606 A MX 2022000606A MX 2022000606 A MX2022000606 A MX 2022000606A MX 2022000606 A MX2022000606 A MX 2022000606A
- Authority
- MX
- Mexico
- Prior art keywords
- fluoroethyl
- difluoromethyl
- sulfonyl
- methyl
- rboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962874855P | 2019-07-16 | 2019-07-16 | |
| PCT/US2020/042028 WO2021011586A1 (en) | 2019-07-16 | 2020-07-15 | Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022000606A true MX2022000606A (es) | 2022-03-11 |
Family
ID=71895284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000606A MX2022000606A (es) | 2019-07-16 | 2020-07-15 | Formas polimorficas de (r)-4-(1-((3-(difluorometil)-1-metil-1h-pir azol-4-il)sulfonil)-1-fluoroetil)-n-(isoxazol-3-il)piperidin-1-ca rboxamida. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20210053939A1 (https=) |
| EP (1) | EP3999504A1 (https=) |
| JP (2) | JP2022540678A (https=) |
| KR (1) | KR20220035176A (https=) |
| CN (1) | CN114127061A (https=) |
| AU (1) | AU2020315605A1 (https=) |
| BR (1) | BR112022000474A2 (https=) |
| CA (1) | CA3143965A1 (https=) |
| CL (1) | CL2022000050A1 (https=) |
| CO (1) | CO2022000117A2 (https=) |
| IL (1) | IL289817A (https=) |
| MX (1) | MX2022000606A (https=) |
| PE (1) | PE20220645A1 (https=) |
| WO (1) | WO2021011586A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116082326B (zh) * | 2022-12-16 | 2024-12-27 | 药康众拓(江苏)医药科技有限公司北京分公司 | 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途 |
| CN117865941B (zh) * | 2024-03-13 | 2024-06-28 | 上海方予健康医药科技有限公司 | 取代哌啶化合物及其制备方法和应用 |
| WO2025244956A1 (en) | 2024-05-20 | 2025-11-27 | MyoKardia, Inc. | Methods of manufacturing danicamtiv |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0007784A (pt) | 1999-01-27 | 2002-02-05 | American Cyanamid Co | Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto |
| WO2005117882A2 (en) | 2004-04-20 | 2005-12-15 | Incyte Corporation | Hydroxamic acid derivatives as metalloprotease inhibitors |
| JP5080970B2 (ja) | 2004-06-17 | 2012-11-21 | サイトキネティクス・インコーポレーテッド | 心疾患を治療するための置換尿素誘導体 |
| AR055831A1 (es) | 2004-12-30 | 2007-09-12 | Janssen Pharmaceutica Nv | Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos |
| KR100979577B1 (ko) | 2005-03-03 | 2010-09-01 | 에프. 호프만-라 로슈 아게 | 2형 진성 당뇨병의 치료를 위한11-베타-하이드록시스테로이드 탈수소효소의 억제제로서1-설폰일-피페리딘-3-카복실산 아마이드 유도체 |
| WO2008120759A1 (ja) | 2007-03-30 | 2008-10-09 | Japan Tobacco Inc. | ウレア化合物およびその用途 |
| US8461209B2 (en) | 2007-06-20 | 2013-06-11 | Mitsubishi Tanabe Pharma Corporation | Malonic acid sulfonamide derivative and pharmaceutical use thereof |
| US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| RU2443699C2 (ru) | 2007-09-20 | 2012-02-27 | Айрм Ллк | Соединения и композиции в качестве модуляторов активности gpr119 |
| CN101801952A (zh) | 2007-10-01 | 2010-08-11 | 弗·哈夫曼-拉罗切有限公司 | 用作ccr受体拮抗剂的n-杂环联芳基甲酰胺类化合物 |
| MX2010003868A (es) | 2007-10-09 | 2010-04-27 | Hoffmann La Roche | Cis-imidazolinas quirales. |
| CN102123990B (zh) | 2008-06-19 | 2014-07-09 | 武田药品工业株式会社 | 杂环化合物及其用途 |
| US8324178B2 (en) | 2008-10-31 | 2012-12-04 | The Regents Of The University Of California | Method of treatment using alpha-1-adrenergic agonist compounds |
| WO2010113377A1 (ja) | 2009-04-01 | 2010-10-07 | パナソニック株式会社 | デジタル周波数／位相ロックドループ |
| CN102596949B (zh) | 2009-11-11 | 2015-08-19 | 大日本住友制药株式会社 | 8-氮杂双环[3.2.1]辛烷-8-甲酰胺衍生物 |
| WO2015005305A1 (ja) | 2013-07-09 | 2015-01-15 | 小野薬品工業株式会社 | Ａｌｘｒ作動化合物 |
| NZ717552A (en) | 2013-08-07 | 2021-07-30 | Merck Patent Gmbh | Piperidine urea derivatives |
| PL3636649T3 (pl) | 2014-01-24 | 2024-05-06 | Turning Point Therapeutics, Inc. | Diaryle makrocykliczne jako modulatory kinaz białkowych |
| IL295547A (en) | 2015-01-22 | 2022-10-01 | Myokardia Inc | Piperidine-4-methylsulfonyl-modified urea compounds for the treatment of dilated cardiomyopathy (dcm) |
| WO2020236736A1 (en) | 2019-05-19 | 2020-11-26 | MyoKardia, Inc. | Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide |
-
2020
- 2020-07-15 EP EP20750115.6A patent/EP3999504A1/en active Pending
- 2020-07-15 AU AU2020315605A patent/AU2020315605A1/en active Pending
- 2020-07-15 KR KR1020227004725A patent/KR20220035176A/ko active Pending
- 2020-07-15 JP JP2022502486A patent/JP2022540678A/ja active Pending
- 2020-07-15 PE PE2022000049A patent/PE20220645A1/es unknown
- 2020-07-15 MX MX2022000606A patent/MX2022000606A/es unknown
- 2020-07-15 US US16/929,230 patent/US20210053939A1/en not_active Abandoned
- 2020-07-15 CN CN202080051794.8A patent/CN114127061A/zh active Pending
- 2020-07-15 CA CA3143965A patent/CA3143965A1/en active Pending
- 2020-07-15 WO PCT/US2020/042028 patent/WO2021011586A1/en not_active Ceased
- 2020-07-15 BR BR112022000474A patent/BR112022000474A2/pt unknown
-
2022
- 2022-01-10 CL CL2022000050A patent/CL2022000050A1/es unknown
- 2022-01-12 CO CONC2022/0000117A patent/CO2022000117A2/es unknown
- 2022-01-12 IL IL289817A patent/IL289817A/en unknown
- 2022-02-23 US US17/678,569 patent/US12459919B2/en active Active
-
2025
- 2025-07-04 JP JP2025113468A patent/JP2025148397A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210053939A1 (en) | 2021-02-25 |
| JP2025148397A (ja) | 2025-10-07 |
| JP2022540678A (ja) | 2022-09-16 |
| US20220289709A1 (en) | 2022-09-15 |
| PE20220645A1 (es) | 2022-04-28 |
| IL289817A (en) | 2022-03-01 |
| CO2022000117A2 (es) | 2022-01-17 |
| US12459919B2 (en) | 2025-11-04 |
| BR112022000474A2 (pt) | 2022-05-17 |
| CA3143965A1 (en) | 2021-01-21 |
| CN114127061A (zh) | 2022-03-01 |
| TW202116765A (zh) | 2021-05-01 |
| AU2020315605A1 (en) | 2022-03-03 |
| CL2022000050A1 (es) | 2022-10-14 |
| EP3999504A1 (en) | 2022-05-25 |
| KR20220035176A (ko) | 2022-03-21 |
| WO2021011586A1 (en) | 2021-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2022000172A (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd) | |
| CL2022000050A1 (es) | Formas polimórficas de (r)-4- (1-((3- (difluorometil)-1-metil-1h-pirazol-4-il)sulfonil) -1-fluoroetil)-n-(isoxazol-3-il)piperidina -1-carboxamida | |
| CO2021015505A2 (es) | Tratamiento de la disfunción sistólica e insuficiencia cardíaca con fracción de eyección reducida con el compuesto (r) -4-(1-((3-(difluorometil) -1-metil-1h-pirazol-4-il) sulfonil) -1-fluoroetil) -n-(isoxazol-3-il) piperidin-1-carboxamida | |
| MX2015017865A (es) | Compuestos de pirimidinodiona contra estados cardiacos. | |
| BR112022000494A2 (pt) | Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica | |
| CL2020000427A1 (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos. | |
| CL2021001083A1 (es) | Compuestos de pirimidinodiona bicíclicos sustituidos con tetrahidropirano (thp) | |
| CO2019000471A2 (es) | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de ácido lisofosfatídico (lpa) | |
| CL2020001931A1 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas. | |
| BR112019009129A2 (pt) | compostos mono e espirocíclicos contendo ciclobutano e azetidina como inibidores de alfa v integrina | |
| PE20200924A1 (es) | Compuestos de bisamida sustituida que activan el sarcomero cardiaco | |
| ECSP088791A (es) | Compuestos pirazólicos heterobicíclicos y métodos de uso. | |
| MX2019005243A (es) | Derivados de indazol como antagonistas de integrina alfa v. | |
| MX378160B (es) | Moduladores del receptor acoplado a la proteina g 40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes. | |
| CO2020009177A2 (es) | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat) | |
| MX2020007759A (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas. | |
| DOP2024000165A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| GEAP202115045A (en) | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | |
| MX2023012758A (es) | Composiciones y metodos para el tratamiento de la enfermedad ocular asociada con angiogenesis. | |
| SG11202008536QA (en) | Compounds for treatment of cardiac arrhythmias and heart failure | |
| MX2021003516A (es) | Compuesto de aminopirimidina. | |
| CO2024017046A2 (es) | Composiciones y métodos para tratar una enfermedad cardíaca | |
| GT200900150A (es) | Nuevos compuestos azabiciclicos, un proceso para su preparacion y las composiciones farmaceuticas que los contienen. | |
| UY37530A (es) | [4-(fenilsulfonil)piperazin-1-il](1h-1,2,3-triazol-4-il)metanonas | |
| Slatinski et al. | Diagnostic challenges in treating patient with cardiogenic shock caused by Lyme disease |